|
| 38010044 | Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary. | Future Oncol | 2024 |
| 36706345 | Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study. | JCO Clin Cancer Inform | 2023 |
| 37742993 | Non-small Cell Lung Cancer Epigenomes Exhibit Altered DNA Methylation in Smokers and Never-smokers. | Genomics Proteomics Bioinformatics | 2023 |
| 37783809 | Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. | NPJ Precis Oncol | 2023 |
| 36993328 | Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer. | Res Sq | 2023 |
| 36949070 | Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. | Nat Commun | 2023 |
| 37285399 | Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. | Sci Transl Med | 2023 |
| 37438216 | Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data. | Clin Lung Cancer | 2023 |
| 37098232 | Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated <i>KRAS</i> G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. | J Clin Oncol | 2023 |
| 37034206 | Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition. | Am J Cancer Res | 2023 |
| 37195052 | Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 36480766 | Clonal Hematopoiesis and Risk of Incident Lung Cancer. | J Clin Oncol | 2023 |
| 36689692 | Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. | J Clin Oncol | 2023 |
| 36504141 | Trends in Stage I Lung Cancer. | Clin Lung Cancer | 2023 |
| 36868177 | Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. | Lung Cancer | 2023 |
| 33106284 | Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a paediatric patient taking zonisamide. | Eur J Hosp Pharm | 2022 |
| 35706127 | Developmental Pathways Are Epigenetically Reprogrammed during Lung Cancer Brain Metastasis. | Cancer Res | 2022 |
| 35545172 | Increased Reach and Effectiveness With a Low-Burden Point-of-Care Tobacco Treatment Program in Cancer Clinics. | J Natl Compr Canc Netw | 2022 |
| 35700081 | A Phase I Study of Apolizumab, an Anti-HLA-DR ÿ-chain Monoclonal Antibody, in Patients With Solid Tumor Malignancies. | Am J Clin Oncol | 2022 |
| 35640927 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. | J Immunother Cancer | 2022 |
| 35693589 | Bone metastases in non-small cell lung cancer: a narrative review. | J Thorac Dis | 2022 |
| 35454817 | Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy. | Cancers (Basel) | 2022 |
| 35419282 | Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. | Front Oncol | 2022 |
| 36179540 | Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors. | Lung Cancer | 2022 |
| 36027916 | Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. | Cancer Cell | 2022 |
| 35074432 | Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 35188825 | Reply to G. Bi et al. | J Clin Oncol | 2022 |
| 35066360 | Targeting KRAS G12C mutation in lung adenocarcinoma. | Lung Cancer | 2022 |
| 35086946 | Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancer. | J Immunother Cancer | 2022 |
| 35331641 | Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | Clin Lung Cancer | 2022 |
| 34996889 | Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. | Nat Commun | 2022 |
| 35297944 | Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). | JAMA Oncol | 2022 |
| 34838325 | Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. | Lung Cancer | 2022 |
| 34446379 | Point of care tobacco treatment sustains during COVID-19, a global pandemic. | Cancer Epidemiol | 2022 |
| 33417483 | Adjuvant Therapy With EGFR Tyrosine Kinase Inhibitors: Tempering Great Expectations With Realism. | J Clin Oncol | 2021 |
| 35590147 | Liquid biopsies for residual disease and recurrence. | Med | 2021 |
| 33718025 | Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer patients. | Transl Lung Cancer Res | 2021 |
| 33683919 | Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. | J Clin Oncol | 2021 |
| 33626341 | Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. | Cell Rep | 2021 |
| 33878954 | Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). | Immunotherapy | 2021 |
| 33820783 | A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. | Clin Cancer Res | 2021 |
| 33643895 | <i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+). | Front Oncol | 2021 |
| 34591593 | Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. | J Clin Oncol | 2021 |
| 34436928 | Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. | J Clin Oncol | 2021 |
| 34429404 | Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. | Nat Commun | 2021 |
| 34809804 | Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation. | J Thorac Oncol | 2021 |
| 34422335 | A phase II study of everolimus in patients with advanced solid malignancies with <i>TSC1, TSC2, NF1, NF2</i> or <i>STK11</i> mutations. | J Thorac Dis | 2021 |
| 34293339 | FTIR based approach to study EnaC mechanosensory functions. | Prog Biophys Mol Biol | 2021 |
| 34096690 | Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation. | N Engl J Med | 2021 |
| 34339292 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. | J Clin Oncol | 2021 |